

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8082526

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
STRECK, INC.	02/10/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	STRECK LLC
<b>Street Address:</b>	7002 S. 109TH STREET
<b>City:</b>	LA VISTA
<b>State/Country:</b>	NEBRASKA
<b>Postal Code:</b>	68128
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	10006861
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)474-0448
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	312-474-6300
<b>Email:</b>	docket@marshallip.com
<b>Correspondent Name:</b>	MARSHALL, GERSTEIN & BORUN
<b>Address Line 1:</b>	233 SOUTH WACKER DRIVE
<b>Address Line 2:</b>	6300 WILLIS TOWER
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60606-6357
<b>ATTORNEY DOCKET NUMBER:</b>	32895/50025
<b>NAME OF SUBMITTER:</b>	CONOR S. HUNT
<b>SIGNATURE:</b>	/Conor S. Hunt/
<b>DATE SIGNED:</b>	07/27/2023
<b>Total Attachments: 52</b>	
source=Streck Inc to LLC Assignment_14911671_10006861#page1.tif	
source=Streck Inc to LLC Assignment_14911671_10006861#page2.tif	
source=Streck Inc to LLC Assignment_14911671_10006861#page3.tif	
source=Streck Inc to LLC Assignment_14911671_10006861#page4.tif	
source=Streck Inc to LLC Assignment_14911671_10006861#page5.tif	



## ASSIGNMENT OF INTELLECTUAL PROPERTY

This ASSIGNMENT OF INTELLECTUAL PROPERTY (this "Agreement"), dated as of February 10, 2023, is entered into by and between Streck, Inc., a Nebraska corporation at 7002 S. 109th Street, La Vista NE 68128 ("Assignor"), and Streck LLC, a Delaware limited liability company at 7002 S. 109th Street, La Vista NE 68128 ("Assignee"). Capitalized terms used but not defined herein shall have their respective meanings as set forth in the Contribution Agreement (as defined below).

### BACKGROUND

WHEREAS, each of Assignor and Assignee is party to that certain Contribution and Assignment Agreement, dated as of the date hereof (the "Contribution Agreement"), pursuant to which Assignor has agreed to assign, transfer, convey and deliver to Assignee, and Assignee has agreed to accept from Assignor, substantially all of Assignor's assets used in the Business (the "Transactions");

WHEREAS, the Contribution Agreement contemplates execution of this Agreement; and

WHEREAS, Assignor desires to transfer to Assignee, and Assignee desires to receive from Assignor, all of Assignor's right, title and interest in and to the IP Assets (as defined below), including all intellectual property rights therein and thereto, and all goodwill associated therewith.

NOW THEREFORE, in consideration of the mutual promises provided herein, the Contribution Agreement, and for other good and valuable consideration, the receipt and adequacy of which each party hereby acknowledges, and intending to be legally bound hereby, the parties agree as follows:

### AGREEMENT

1. **ASSIGNMENT.** Assignor hereby irrevocably and unconditionally grants, conveys, transfers and assigns to Assignee all of Assignor's (a) worldwide right, title, and interest in and to (i) all copyrights used or held for use in the operation of the Business as conducted in the past or at present or as expected to be conducted in the future (including all common law rights and applications and registrations for the foregoing, including, without limitation, the applications and registrations set forth on Exhibit A), (ii) all patent rights used or held for use in the operation of the Business as conducted in the past or at present or as expected to be conducted in the future, including, without limitation, the applications and issued patents set forth on Exhibit A, and all future patents that may issue from such patent rights throughout the world, all divisionals, continuations in whole or in part, reexaminations, reissues, substitutions or extensions of any of the foregoing, all foreign counterparts to any of the foregoing, and the right to claim priority to the same), (iii) all trademark, trade name, and service mark rights, in each case used or held for use in the operation of the Business as conducted in the past or at present or as expected to be conducted in the future (including all common law rights and applications and registrations for the foregoing, including, without limitation, the applications and registrations set forth on Exhibit A, and the right to claim priority to the same and all renewals thereof), together with the goodwill of the Business symbolized by and associated with the foregoing, (iv) all other intellectual property used or held for use in the operation of the Business as conducted in the past or at present or as expected to be

conducted in the future, (v) all trade secrets and confidential business information (including confidential ideas, research and development, know-how, methods, formulas, compositions, manufacturing and production processes and techniques, technical and other data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), (vi) all websites, computer software and firmware (including source code, executable code, data, databases, user interfaces, algorithms and related documentation) (subsections (i) through (vi) collectively, the "IP Assets") and (vii) all other proprietary or intellectual property rights of any kind or nature throughout the world, in all cases that pertain to or that are embodied by or in any of the IP Assets or are used or held for use in the operation of the Business as conducted in the past or at present or as expected to be conducted in the future (collectively, the "Intellectual Property Rights"), and (b) worldwide rights to income, royalties, and license fees deriving from the IP Assets and/or Intellectual Property Rights, claims for damages by reason of past, present and future infringement or misappropriation of the IP Assets and/or Intellectual Property Rights or injury to the goodwill associated with the Intellectual Property Rights, and the right to sue for and collect such damages, as permitted under the applicable laws for any jurisdiction or country in which such claims may be asserted for the use and benefit of Assignee and its successors, assigns and other legal representatives, same to be held by Assignee for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns and other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Agreement had not been made.

2. **UNASSIGNABLE IP.** If any Intellectual Property Rights in or to the IP Assets cannot be assigned as a matter of law (the "Unassignable IP Rights"), Assignor hereby grants to Assignee an exclusive (without reservation), irrevocable, perpetual, worldwide, transferable, fully-paid and royalty-free license, with the right to sublicense through multiple tiers, under the Unassignable IP Rights, to (a) reproduce, create derivative works of, distribute, publicly perform, publicly display, and otherwise use the IP Assets and related Intellectual Property Rights in any medium or format, whether now known or hereafter discovered, (b) use, make, have made, sell, offer to sell, import, and otherwise exploit any product, process, or service based on, embodying, incorporating, or derived from the IP Assets and/or the related Intellectual Property Rights, and (c) fully utilize, exploit, and exercise any and all other present or future rights with respect to the IP Assets and the Intellectual Property Rights in any manner without restriction, and Assignor hereby unconditionally and irrevocably waives and quitclaims to Assignee any and all claims and causes of action of any kind against Assignee, its successors, assigns, and other legal representatives, and its licensees (through multiple tiers) with respect to such rights, and agrees, at Assignee's request and expense, to consent to and join in any action to enforce such rights. Assignor further waives any "moral" rights, or other rights with respect to attribution of authorship or integrity relating to the IP Assets or related Intellectual Property Rights as Assignor may have under any applicable law under any legal theory.

3. **ASSISTANCE.** From time to time hereafter, and without further consideration, Assignor and its successors and permitted assigns covenant and agree that Assignor and its successors and permitted assigns shall execute and deliver, or shall cause to be executed and delivered, such further instruments of conveyance and transfer and take such additional action as Assignee may reasonably request to effect, consummate, confirm or evidence the transfer to Assignee, its successors and assigns all of the IP Assets and Intellectual Property Rights in accordance with the foregoing, including, without limitation, assistance and cooperation in the registration and enforcement of applicable intellectual property rights or other legal proceedings, including providing documents

and materials in the possession or control of Assignor, testifying in any legal proceedings, signing lawful papers and making all lawful oaths, all of the foregoing at Assignor's expense, and generally doing everything that is reasonable to aid Assignee in obtaining and enforcing proper protection for applicable intellectual property rights and otherwise in the carrying out of the intentions and purposes of this Agreement. If Assignee or its successor or assignee is unable, for any reason, to obtain a signature of Assignor on a document necessary to perfect the transfer or assignment of the IP Assets or the Intellectual Property Rights, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents, as Assignor's agents and attorneys-in-fact to act for and on Assignor's behalf and instead of Assignor, solely to execute and file any such document and to do all other lawfully permitted acts to further the purposes of this Agreement with the same legal force and effect as if executed by Assignor.

4. **RECORDATION.** Assignor authorizes the U.S. Commissioner for Patents and the U.S. Commissioner for Trademarks at the U.S. Patent and Trademark Office and any other governmental officials of any patent or trademark office worldwide to record and register this Agreement (or a redacted version thereof) upon request by Assignee.

5. **GENERAL.**

5.1 **Expenses.** Except as otherwise provided in Section 3 hereof, Assignor shall pay all costs and expenses incurred by Assignor on its behalf in connection with this Agreement, including fees and expenses of its financial consultants, accountants and counsel. Assignee shall pay all costs and expenses incurred by Assignee or on its behalf in connection with this Agreement, including fees and expenses of its financial consultants, accountants and counsel.

5.2 **Exclusive Agreement.** This Agreement (including Exhibit A hereto) and the Contribution Agreement constitutes the sole understanding of the parties with respect to the subject matter hereof. In the event of a conflict between a term or condition of this Agreement and a term or condition of the Contribution Agreement with respect to the subject matter hereof, the term or condition of this Agreement shall control.

5.3 **Governing Law; Venue; Waiver of Jury Trial.** This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware applicable to agreements made and to be performed wholly within such jurisdiction, without regard to principles of conflicts of laws. Each of the parties hereby irrevocably and unconditionally (a) consents to submit to the exclusive jurisdiction of the courts of the State of Delaware and the United States located in the County of New Castle for any Proceeding arising out of or relating to this Agreement (and agrees not to commence any Proceeding relating thereto except in such courts), (b) waives and agrees not to plead or claim in any such court that any Proceeding brought in any such court that any such Proceeding brought in any such court has been brought in an inconvenient forum, and (c) waives any and all right to trial by jury in any Proceeding arising out of or related to this Agreement or events contemplated hereby or any course of conduct, course of dealing, statements (whether verbal or written) or actions of any party.

5.4 **Successors and Assigns.** This Agreement will be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Agreement may not be assigned or delegated by Assignor without the prior written consent of Assignee, and any attempted assignment by Assignor without such consent shall be null and void. No permitted

assignment by Assignor shall relieve Assignor of its obligations hereunder. Assignee may assign its rights or delegate its responsibilities, liabilities and obligations under this Agreement, in whole or in part, without the consent of Assignor.

**5.5 Severability.** (a) If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transactions is not affected in any adverse manner to any party and (b) upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner so that the Transactions are fulfilled to the greatest extent possible.

**5.6 Counterparts.** This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. For the convenience of the parties, any number of counterparts hereof may be executed, each such executed counterpart shall be deemed an original and all such counterparts together shall constitute one and the same instrument. Facsimile transmission (including the e-mail delivery of documents in Adobe PDF format) of any signed original counterpart and/or retransmission of any signed facsimile transmission shall be deemed the same as the delivery of an original.

**5.7 Interpretation.** The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. This Agreement has been drafted and negotiated by all parties, the language set forth herein shall be deemed to be the language of all parties and no rule of strict construction shall be applied against any party. Any drafts of this Agreement prior to the final fully executed draft shall not be used for purposes of interpreting any provision of this Agreement, and each of the parties agrees that no party hereto shall make any claim, assert any defense or otherwise take any position inconsistent with the foregoing in connection with any dispute or Proceeding among any of the foregoing or for any other purpose.

**5.8 Amendments.** This Agreement may not be amended except by an instrument in writing signed by Assignee and Assignor.

*[Remainder of Page Intentionally Blank]*

ASSIGNEE:

STRECK LLC

By: Constance M. Ryan  
Name: Constance M. Ryan  
Its: Chief Executive Officer

STATE OF NEBRASKA ) ss.:


COUNTY OF SARPY )

On February 10, 2023 before me, Alexis Boyd, personally appeared Constance Ryan who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of Nebraska that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Alexis Boyd (Seal)



IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto.

ASSIGNOR:

STRECK, INC.

By: Constance M. Ryan  
Name: Constance M. Ryan  
Its: Chief Executive Officer

STATE OF NEBRASKA ) ss.:


COUNTY OF SARPY )

On February 10, 2023 before me, Alexis Boyd, personally appeared Constance Ryan who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of Nebraska that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Alexis Boyd (Seal)



[SIGNATURE PAGE TO ASSIGNMENT OF INTELLECTUAL PROPERTY]



**EXHIBIT A – IP Assets****United States of America****(i) Copyrights**

<b>Title</b>	<b>Registration No.</b>	<b>Registration Date</b>
55220-deposit copy – Streck Drawings	VA0002016652	9/13/2016
Cell-Free DNA BCT Instructions	TX0008234059	8/26/2016
CF #3	TX0008696996	3/28/2019
CF #5 IFU	TX0008699335	3/28/2019
Philisa Source Code with Screen Display	TX0007462908	10/26/2011
Philisa Thermal Cycler Source Code	TXu001748397	1/13/2011
Streck Website Content	TX0008389125	2/6/2017
Owl Drawing	2021-F-01232607	1/13/2021

**(ii) Patents****Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Cis, di-ahl modified for glycated hemoglobin s-A1c Derived from healthy blood cells	US 8551784	11/17/2011	10/08/2013
Method of preparing controls for glycated hemoglobin S-A1c derived from healthy blood cells	US 8546144	11/17/2011	10/01/2013
Blood collection tube with surfactant	US 7767460	06/10/2008	8/03/2010
Blood collection tube with surfactant	US 7419832	03/07/2006	9/02/2008
Blood collection and testing improvements	US 7608457	03/10/2005	10/07/2009
Inactivated virus compositions and methods of preparing such compositions	US 9956281	10/17/2013	5/01/2018
Blood sample tube label	US D637235	10/14/2009	5/03/2011
Blood sample tube label	US D637234	09/13/2010	5/03/2011
Method and device for collecting and preserving cells for analysis	US 10966421	10/16/2003	4/06/2021
Preservation of cell-free RNA in blood samples	US 8304187	02/11/2010	11/6/2012
Preservation of cell-free RNA in blood samples	US 9657227	11/05/2013	5/23/2017
Devices and compositions for preservation of cell-free nucleic acids	US 9926590	05/22/2017	3/27/2018
Methods for the preservation of cell-free nucleic acids	US 10144955	02/12/2018	12/4/2018
Preservation of cell-free nucleic acids	US 10294513	03/27/2018	5/21/2019
Preservation of cell-free nucleic acids	US 10689686	04/08/2019	6/22/2020

**EXHIBIT A -- IP Assets**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Compositions and methods for stabilizing circulating tumor cells	US 10091984	01/22/2016	10/09/2018
Compositions and methods for stabilizing circulating tumor cells	US 10674721	10/05/2018	06/09/2020
Compositions and methods for stabilizing circulating tumor cells	US 11547111	06/08/2020	01/10/2023
Single spin process for blood plasma separation and plasma composition including preservative	US 11299764	12/27/2018	04/12/2022
Stabilization of nucleic acids in urine	US 11168351	03/07/2016	11/09/2021
Sample tube	US D659848	04/22/2011	5/15/2012
CLAIM The ornamental design for a sample tube, as shown and described	US D690025	06/11/2012	9/17/2013
Sample tube having a particular utility for nucleic acid amplification	US 8889086	04/20/2012	11/18/2014
Thermocycler and sample vessel for rapid amplification of DNA	US 9034635	10/27/2010	5/19/2015
Devices for real-time polymerase chain reaction	US 10006861	02/11/2016	6/26/2018
Devices for real-time polymerase chain reaction	US 11385178	06/25/2018	7/12/2022
Real-time optical system for polymerase chain reaction	US 9932632	03/15/2013	4/3/2018
Rapid thermocycler system for rapid amplification of nucleic acids and related methods	US 9737891	05/31/2012	8/22/2017
Laboratory analysis device housing	US D665,917	09/02/2011	8/21/2012
Laboratory analysis device housing	US D784,549	04/28/2015	4/18/2017
Suspension composition for hematology analysis control	US 11506655	01/29/2019	11/22/2022

**Patent Applications**

<b>Title</b>	<b>Application Serial No.</b>	<b>Filing Date</b>
Suspension composition for hematology analysis control	US 17/973220	10/25/2022
Method and device for collecting and preserving cells for analysis	US 12/850269	08/04/2010
Method and device for collecting and preserving cells for analysis	US 15/010,549	01/29/2016
Method and device for collecting and preserving cells for analysis	US 17/182145	02/22/2021
Preservation of fetal nucleic acids in maternal plasma	US 12/689,370	01/19/2010
Preservation of cell-free nucleic acids	US 16/908,233	07/02/2020

**EXHIBIT A – IP Assets**



<b>Title</b>	<b>Application Serial No.</b>	<b>Filing Date</b>
Blood Collection Device for Improved Nucleic Acid Regulation	US 16/861150	04/28/2020
Compositions and methods for stabilizing circulating tumor cells	US 16/895292	06/08/2020
Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles	US 16/756,803	10/19/2018
Methods of preparing samples for proteomic analysis	US 17/417,234	12/27/2019
Methods of preparing samples for proteomic analysis	US 18/012054	12/28/2022
Stabilization of nucleic acids in urine	US 17/521,350	11/08/2021
Molecular reference controls	US 16/324411	08/11/2017
Assays and methods for determining microbial resistance	US 16/310,074	6/15/2017
Detection of antibiotic resistance genes	US 17/614892	11/29/2021
Devices for real-time polymerase chain reaction	US 17/843132	06/17/2022

(iii) Trademarks

Trademark Registrations

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
A1C-CELLULAR		U.S.	78/544055	01/07/2005	3134491	08/22/2006
ARM-D		U.S.	86/541458	02/20/2015	4826697	10/06/2015
CAL-CHEX		U.S.	88/939116	05/29/2020	6227474	12/22/2020
CD-CHEX CD103 PLUS		U.S.	87/420237	04/21/2017	5405136	02/20/2018
CD-CHEX CD117		U.S.	86/112984	11/07/2013	4779898	07/28/2015
CD-CHEX CD34		U.S.	86/112971	11/07/2013	4779897	07/28/2015
CD-CHEX PLUS		U.S.	86/112962	11/07/2013	4779896	07/28/2015
CD-CHEX SELECT		U.S.	86/112951	11/07/2013	4792791	08/18/2015
CD-CHEX TDT PLUS		U.S.	87/420233	04/21/2017	5329558	11/07/2017
CELL-CHEX		U.S.	85/410938	08/30/2011	4166939	07/03/2012
CELL-FREE DNA BCT		U.S.	85/785470	11/21/2012	4450121	12/17/2013
CELL-FREE RNA BCT		U.S.	85/785523	11/21/2012	4450122	12/17/2013
CYTO-CHEX		U.S.	76/375017	02/26/2002	2668866	12/31/2002
CYTO-CHEX		U.S.	77/479291	05/20/2008	3634052	06/09/2009
ESR-AUTO PLUS		U.S.	78/586678	03/14/2005	3063564	02/28/2006

EXHIBIT A – IP Assets

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
ESR-CHEX		U.S.	88/939112	05/29/2020	6414447	07/13/2021
FUSION2		U.S.	87/195,959	10/07/2016	5481844	05/29/2018
FUSION2 (Stylized)	<i>FUSION</i>	U.S.	87/201,095	10/12/2016	5481854	05/29/2018
OWL LOGO		U.S.	87/477123	06/06/2017	5455068	04/24/2018
PARA 12		U.S.	73/447491	10/11/1983	1317494	02/05/1985
PARA 4		U.S.	87/080205	06/22/2016	5119475	01/10/2017
RETIC-CHEX		U.S.	73/710533	02/10/1988	1510645	11/01/1988
RNA COMPLETE BCT		U.S.	88/143735	10/04/2018	6114200	07/28/2020
SICKLE-CHEX		U.S.	76/375212	02/26/2002	2677465	01/21/2003
SICKLEDEX		U.S.	72/319349	02/17/1969	889582	04/21/1970
SPERM-CHEX		U.S.	86/750003	09/08/2015	5211633	05/30/2017
STAK-CHEX		U.S.	75/623750	01/19/1999	2335221	03/28/2000
STATS		U.S.	87/424347	04/25/2017	5462185	05/08/2018
STATS-LINK		U.S.	76/457605	10/11/2002	2752589	08/19/2003
STRECK		U.S.	85/048932	05/27/2010	3877128	11/16/2010
STRECK & OWL LOGO	STRECK 	U.S.	87/477069	06/06/2017	5460603	05/01/2018
STRECK (BLOCK LETTERS)	<b>STRECK</b>	U.S.	87/476565	06/06/2017	5455067	04/24/2018
STRECK (STYLIZED)	<i>Streck</i>	U.S.	85/048942	05/27/2010	3877129	11/16/2010
STRECK CELL PRESERVATIVE		U.S.	88/939108	05/29/2020	6617641	01/18/2022
STRECK STYLIZED - COLOR	<i>Streck</i>	U.S.	78/516235	11/12/2004	3080822	04/11/2006
SUGAR-CHEX		U.S.	74/157012	04/15/1991	1726948	10/27/1992
TEMP-CHEX		U.S.	88/939199	05/29/2020	6903662	11/22/2022
THE SCIENCE OF TRUST		U.S.	88/466212	06/10/2019	6076382	06/09/2020
UA-CELLULAR		U.S.	85/048959	05/27/2010	3846846	09/07/2010
VC-100		U.S.	73/476345	04/20/1984	1363011	10/01/1985
ZULU RT		U.S.	87/036,022	05/13/2016	5408190	02/20/2018

**EXHIBIT A – IP Assets**

Trademark Applications

Trademark	Mark Image	Country	Application No.	Application Date
MDX-CHEX		U.S.	90/812378	07/06/2021

Trade Names

HQ-Chex  
ESR-10  
Pipet Verification Service (PVS)

(iv) Other Intellectual Property for use in Operation of the Business

Exclusive Intellectual Property Licenses

Title	Owner	Patent No.	Date Filed	Issue Date
Multiplex PCR for the detection of ampC beta-lactamase genes	Creighton University	US 7045291	05/17/2002	05/16/2006

Intellectual Property Licenses

1. License from Creighton University under License Agreement with Effective Date May 1, 2013 for use of:
  - a. U.S. Patent No. 7,045,291
2. License from KMC Software under License Agreement with an Effective Date April 19, 2018 for use of:
  - a. KMC Software, Source Code, and Object Code
3. License from American Type Culture Collection (ATCC) Biological Materials under Non-Exclusive Biological Material License Agreement with an Effective Date of July 25, 2019 and subsequent amendments for use of:
  - a. ATCC Biological Materials ATCC BAA-2802; ATCC 10231; ATCC 2001; ATCC 14243; ATCC 22019; ATCC 750; ATCC BAA-2807; ATCC 13047; ATCC 51299; ATCC 700221; ATCC BAA-2776; ATCC 49766; ATCC 51697; ATCC 49131; ATCC 35657; ATCC 19115; ATCC 4698; ATCC 13077; ATCC 13813; ATCC 49619; ATCC 19615; ATCC 25933; ATCC BAA-2793; ATCC 43862; ATCC BAA-2094; ATCC 14990; ATCC 49576; ATCC 33397; ATCC CRL-1929; ATCC 13637; ATCC 13880; ATCC 25285; ATCC 29906; ATCC 32045; ATCC 51907; TCC BAA-255; ATCC CCL-155; ATCC 27335; ATCC

## EXHIBIT A – IP Assets

BAA-38; and ATCC BAA-1717

4. License from Ceres Nanoscience, Inc. under Distribution Agreement with an Effective Date of September 30, 2021 for use of:
  - a. Patents: US 8238987 B2; US 9005996; US 7935518 B2; US 8497137 B2; US 9383299; US 9012240; CA 2681377; EP 1929299; EP 2132256; EP 2443101B1; JP 494753; JP 5896119; JP 5843085; JP 5828194
  - b. Trademark: Nanotrap®
5. License from Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen under Use Agreement for Commercial Use of Biological Materials, with an Effective Date of December 7, 2020 for use of:
  - a. Microorganism strain DSM 21092

### Software Licenses

- a. License from Crain Communication, Inc. for use of companywide premium license to GenomeWeb via a Subscription Services Agreement effective on August 31, 2022.
- b. License from Stryder Corp. dba Handshake for use of Handshake software subscription via Premium Employer Access Terms and Conditions effective on July 29, 2021.
- c. License from BrightEdge Technologies, Inc. for use of Enterprise SEO Platform subscription via subscription service agreement effective on July 26, 2022.
- d. License from iCIMS, Inc. for use of Access to iCIMS Talent Cloud software via statement of work effective on April 29, 2022.
- e. License from Dell Software, Inc. for use of Enterprise Licenses to Spotlight on SQL Server, and Litespeed Enterprise for SQL Server via agreement effective on October 01, 2020.
- f. License from Proofpoint, Inc. for use of Proofpoint data loss prevention and encryption subscription license via services agreement with supplier GHA Technologies effective on June 01, 2022.
- g. License from Planview, Inc. for use of Planview software via subscription services agreement effective on June 30, 2022.
- h. License from Infor, Inc. for use of Syteline via software license agreement effective May 10, 2022 and Infor CloudSuite via Software License Agreement effective 06/27/2003.
- i. License from PitchBook for use of PitchBook software license via agreement effective April 03, 2022.
- j. License from Patsnap (UK) Ltd. for use of PatSnap software license via agreement effective February 25, 2022.
- k. License from PulseOne for use of AvePoint Cloud Backup for Dynamics 365 via subscription services agreement effective on December 17, 2022.
- l. License from SmartProcure, Inc. for use of SmartProcure and GovSpend software licenses via purchase agreement effective December 03 and 08, 2021,

## EXHIBIT A -- IP Assets

respectively.

- m. Microsoft, CRM Dynamics365 licenses via software license agreement effective December 01, 2021.
- n. License from West Publishing Corporation d/b/a Thomson Reuters Enterprise Centre GmbH for use of Thomson Reuters West Proflex and Practical Law subscription via order form effective January 01, 2022.
- o. License from EtQ Management for use of Life Sciences Quality Management Solution Suite via software license effective November 01, 2021 and Reliance Program via software subscription agreement effective September 25, 2013.
- p. License from inMotionNow, Inc. for use of Lythos software via order agreement effective August 30, 2021.
- q. License from Alteryx for use of Alteryx Designer via software license effective on April 01, 2021.
- r. License from Tenable for use of Tenable.sc, Nessus Agents, Nessus Professional software -- via master agreement effective February 25, 2021.
- s. License from Act-On Software, Inc. for use of Active Contacts Enterprise via subscription agreement effective June 30, 2020.
- t. License from On-Line Imaging, Inc. for use of PSIGEN PSI Capture licenses via agreement effective September 10, 2019.
- u. License from Varonis, Inc. for use of Oracle Software via license agreement effective April 29, 2019.
- v. License from CIMCON Software, Inc. for use of eInfortree software via end-user software and documentation license agreement effective February 18, 2014.
- w. License from LabArchives, LLC for use of LabArchives electronic lab notebook software via enterprise subscription agreement effective November 17, 2017.
- x. License from Ultimate Software for use of UltiPro software via subscription software license agreement effective February 01, 2017.
- y. License from Copyright Clearance Center for use of CCC and Copyright license via agreement effective October 14, 2010.

### (vi) Websites, Computer Software, and Firmware

#### Domain Names

- a. Streck.com -- Registered on 1996-06-29; Expiring on 2024-06-28
- b. Streckcareers.com -- Registered on 2015-05-08; Expiring on 2024-05-08
- c. Abbottapprovalonline.com -- Registered on 2013-01-15; Expiring on 2023-01-15
- d. Abbottapproval.online -- Registered on 2022-06-26; Expiring on 2023-06-26
- e. Keshoinc.com -- Registered on 2017-02-23; Expiring 2023-02-23

EXHIBIT A – IP Assets

**International**

(i) Copyrights

None











(ii) Patents

PCT Applications

Title	Application Serial No.	Filing Date
Sample collection containers, processes and collected samples	PCT/US2021/045874	08/13/2021
Method for spray coating a surface attached hydrogel	PCT/US2022/047199	10/20/2022

(iii) Trademarks

WIPO Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
ARM-D		WIPO	1271279	08/20/2015	1271279	08/20/2015
CELL-FREE DNA BCT		WIPO	1161777	05/06/2013	1161777	05/06/2013
ESR-CHEX		WIPO	1568347	11/24/2020	1568347	11/24/2020
FUSION2		WIPO	1382075	11/14/2017	1382075	11/14/2017
FUSION2		WIPO	1340419	01/23/2017	1340419	01/23/2017
FUSION2 (Stylized)		WIPO	1342860	01/23/2017	1342860	01/23/2017
FUSION2 (Stylized)		WIPO	1383467	11/14/2017	1383467	11/14/2017
MDX-CHEX		WIPO	1661752	01/06/2022	1661752	01/06/2022
OWL LOGO		WIPO	A0069330	08/21/2017	1374847	08/21/2017
OWL LOGO		WIPO	A0069786	09/08/2017	1376232	09/08/2017
SICKLEDEX		WIPO	354374	02/25/1969	354374	02/25/1969
SPERM-CHEX		WIPO	1314633	03/03/2016	1314633	03/03/2016
STRECK		WIPO	1053091	09/10/2010	1053091	09/10/2010
STRECK		WIPO	1374468	08/21/2017	1374468	08/21/2017
STRECK & OWL LOGO		WIPO	A0069781	09/08/2017	1375949	09/08/2017
STRECK & OWL LOGO		WIPO	A0069329	08/21/2017	1374468	08/21/2017
STRECK & OWL LOGO		WIPO	1053091	09/10/2010	1053091	09/10/2010
STRECK (BLOCK LETTERS)		WIPO	1375589	08/22/2017	1375589	08/22/2017
STRECK (BLOCK LETTERS)		WIPO	1374838	09/08/2017	1374838	09/08/2017
STRECK CELL PRESERVATIVE		WIPO	1568401	11/24/2020	1568401	11/24/2020
THE SCIENCE OF		WIPO	1518684	11/21/2019	1518684	11/21/2019

**PATENT**

**REEL: 064417 FRAME: 0566**



EXHIBIT A – IP Assets

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
TRUST						

**EXHIBIT A – IP Assets**

**Europe**

(i) Copyrights

None

(ii) Patents

**European Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Inactivated virus compositions and methods of preparing such compositions	EP 2704740	05/03/2012	10/05/2016
Method and device for collecting and preserving cells for analysis	EP 1816461	10/16/2003	01/08/2020
Method and device for stabilizing proteins	EP 3118623	07/15/2016	05/27/2020
Preservation of fetal nucleic acids in maternal plasma	EP 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	EP 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	EP 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	EP 2814981	02/13/2013	06/28/2017
Blood Collection Device for Improved Nucleic Acid Regulation	EP 3225699	02/13/2013	09/30/2020
Compositions and methods for stabilizing circulating tumor cells	EP 3024323	07/22/2014	10/19/2022
Sample tube	EP 0019285320001	10/06/2011	10/6/2011
Sample tube	EP 0021310110001	11/06/2012	11/6/2012
Thermocycler and sample vessel for rapid amplification of DNA	EP 2255010	02/19/2009	5/30/2018
Laboratory analysis device housing	EP 0019954240001	02/21/2012	02/21/2012
Laboratory analysis device housing	EP 002,836,882,000	10/26/2015	12/03/2015
Assays and methods for determining microbial resistance	EP 3472350	6/15/2017	08/17/2022

**European Patent Applications**

<b>Title</b>	<b>Application Serial No.</b>	<b>Filing Date</b>
Suspension composition for hematology analysis control	EP 17757593.3	07/28/2017
Preservation of fetal nucleic acids in maternal plasma	EP 20160593.8	01/20/2010
Preservation of cell-free nucleic acids	EP 20193258.9	02/28/2020
Blood Collection Device for Improved Nucleic Acid Regulation	EP 201997453.2	09/22/2020

**EXHIBIT A – IP Assets**

Title	Application Serial No.	Filing Date
Compositions and methods for stabilizing circulating tumor cells	EP 22199049.2	09/30/2022
Single spin process for blood plasma separation and plasma composition including preservative	EP 19186944.5	11/22/2016
Sample collection tube with preservative	EP 18747249.3	02/05/2018
Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles	EP 18867969.0	10/19/2018
Methods of preparing samples for proteomic analysis	EP 21756090.3	01/11/2023
Methods of preparing samples for proteomic analysis	EP 19849072.4	12/27/2019
Molecular reference controls	EP 17757980.2	08/11/2017
Assays and methods for determining microbial resistance	EP 22190317.2	10/25/2022
Detection of antibiotic resistance genes	EP 20746765.5	05/29/2020
Devices for real-time polymerase chain reaction	EP 18209191.8	06/30/2014

(iii) Trademarks

European Union Trademark Registrations


Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
ARM-D		E.U.	1271279	08/20/2015	1271279	08/20/2015
CD-CHEX		E.U.	011647559	03/12/2013	011647559	09/06/2013
CELL-FREE DNA BCT		E.U.	1161777	05/06/2013	1161777	05/06/2013
CTC PLUS BCT		E.U.	018047586	04/03/2019	018047586	08/30/2019
CYTO-CHEX		E.U.	006952361	05/30/2008	006952361	02/10/2009
ESR-CHEX		E.U.	1568347	11/24/2020	1568347	11/24/2020
LBC-CHEX		E.U.	011754579	04/19/2013	011754579	09/12/2013
MDX-CHEX		E.U.	1661752	01/06/2022	1661752	01/06/2022
PROTEIN PLUS BCT		E.U.	018047588	04/03/2019	018047588	08/30/2019
RNA COMPLETE BCT		E.U.	018047583	04/03/2019	018047583	08/30/2019
STRECK		E.U.	1053091	09/10/2010	1053091	09/10/2010
STRECK & OWL LOGO	STRECK 	E.U.	A0069329	08/21/2017	1374468	08/21/2017
STRECK (BLOCK LETTERS)	<b>STRECK</b>	E.U.	1375589	08/22/2017	1375589	08/22/2017

EXHIBIT A – IP Assets


STRECK CELL PRESERVATIVE		E.U.	1568401	11/24/2020	1568401	11/24/2020
STRECK STYLIZED - COLOR		E.U.	004354726	03/21/2005	004354726	04/19/2006
THE SCIENCE OF TRUST		E.U.	1518684	11/21/2019	1518684	11/21/2019
ZULU-RT		E.U.	15522031	06/09/2016	15522031	12/14/2016

EXHIBIT A – IP Assets

Australia

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Method and device for collecting and preserving cells for analysis	AU 2003254755	10/16/2003	12/20/2007
Devices for real-time polymerase chain reaction	AU 2014302052	06/30/2014	11/01/2018

Patent Applications

Title	Application Serial No.	Filing Date
Devices for real-time polymerase chain reaction	AU 2021200020	01/04/2021

(iii) Trademarks

Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
ESR-CHEX		Australia	1568347	11/24/2020	1568347	11/24/2020
OWL LOGO		Australia	A0069786	09/08/2017	1376232	09/08/2017
STRECK & OWL LOGO	STRECK 	Australia	A0069781	09/08/2017	1375949	09/08/2017
STRECK (BLOCK LETTERS)	STRECK	Australia	1374838	09/08/2017	1374838	09/08/2017
STRECK CELL PRESERVATIVE		Australia	1568401	11/24/2020	1568401	11/24/2020
THE SCIENCE OF TRUST		Australia	1518684	11/21/2019	1518684	11/21/2019

**EXHIBIT A – IP Assets**

**Austria**

(i) Copyrights

None

(ii) Patents

**Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Method and device for collecting and preserving cells for analysis	AT 1816461	10/16/2003	01/08/2020
Preservation of fetal nucleic acids in maternal plasma	AT 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	AT 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	AT 2814981	02/13/2013	09/30/2020
Blood Collection Device for Improved Nucleic Acid Regulation	AT 3225699	02/13/2013	09/30/2020

(iii) Trademarks

**Trademark Registrations**

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
SICKLEDEX		Austria	354374	02/25/1969	354374	02/25/1969

**EXHIBIT A -- IP Assets**

**Belgium**

(i) Copyrights

None

(ii) Patents

Patent Registrations

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Method and device for collecting and preserving cells for analysis	BE 1816461	10/16/2003	01/08/2020
Method and device for stabilizing proteins	BE 3118623	07/15/2016	05/27/2020
Preservation of fetal nucleic acids in maternal plasma	BE 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	BE 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	BE 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	BE 3225699	02/13/2013	09/30/2020

(iii) Trademarks

None

**EXHIBIT A – IP Assets**

**Bosnia and Herzegovina**

(i) Copyrights

None

(ii) Patents

None

(iii) Trademarks

**Trademark Registrations**

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
<b>SICKLEDEX</b>		<b>Bosnia &amp; Herzegovina</b>	<b>354374</b>	<b>02/25/1969</b>	<b>354374</b>	<b>02/25/1969</b>



## EXHIBIT A – IP Assets

### Canada

#### (i) Copyrights

None

#### (ii) Patents

##### Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Blood collection and testing improvements	CA 2538968	03/08/2006	03/03/2015
Method and device for collecting and preserving cells for analysis	CA 2445204	10/16/2003	08/12/2014
Preservation of fetal nucleic acids in maternal plasma	CA 2690651	01/21/2010	10/04/2016
Preservation of fetal nucleic acids in maternal plasma	CA 2938275	01/21/2010	08/31/2021
Compositions and methods for stabilizing circulating tumor cells	CA 2917912	07/22/2014	09/17/2019
Thermocycler and sample vessel for rapid amplification of DNA	CA 2716337	02/19/2009	11/14/2017

##### Patent Applications



Title	Application Serial No.	Filing Date
Method and device for stabilizing proteins	CA 2936167	07/14/2016
Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles	CA 3079415	10/19/2018
Methods of preparing samples for proteomic analysis	CA 3,124,698	12/27/2019
Stabilization of nucleic acids in urine	CA 2922859	03/07/2016
Assays and methods for determining microbial resistance	CA 3027953	6/15/2017
Detection of antibiotic resistance genes	CA 3140112	05/29/2020
Devices for real-time polymerase chain reaction	CA 2916990	06/30/2014

#### (iii) Trademarks

##### Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
CD-CHEX		Canada	1618125	03/13/2013	TMA 900677	04/09/2015
ESR-CHEX		Canada	2074606	11/24/2020	TMA 1138831	08/17/2022

EXHIBIT A – IP Assets

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
OWL LOGO		Canada	1857501	09/14/2017	TMA 1074432	03/06/2020
PHILISA		Canada	1490307	07/27/2010	TMA 823769	05/10/2012
STRECK		Canada	1497646	09/28/2010	TMA 835564	11/01/2012
STRECK & OWL LOGO	STRECK 	Canada	1857504	09/14/2017	TMA 1074515	03/06/2020
STRECK (BLOCK LETTERS)	STRECK	Canada	1857505	09/14/2017	TMA 1093540	02/11/2021
THE SCIENCE OF TRUST		Canada	2015514	11/21/2019	TMA 1157033	12/21/2022

Trademark Applications

Trademark	Mark Image	Country	Application No.	Application Date
STRECK CELL PRESERVATIVE		Canada	1568401	11/24/2020

**EXHIBIT A -- IP Assets**

**China**

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles	CN 111372451	04/01/2020	8/12/2022

Patent Applications

Title	Application Serial No.	Filing Date
Sample collection tube with preservative	CN 201880023537.6	02/05/2018
Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles	CN 202210914794.7	10/19/2018
Methods of preparing samples for proteomic analysis	CN pending for PCT/US21/39870	12/21/2022

(iii) Trademarks

Trademark Registrations




Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
CELL-FREE DNA BCT		China	1161777	05/06/2013	1161777	05/06/2013
ESR-CHEX		China	1568347	11/24/2020	1568347	11/24/2020
OWL LOGO		China	36344344	02/15/2019	36344344	01/28/2020
STRECK		China	43984649	02/03/2020	43984649	08/07/2021
STRECK		China	43984642	02/03/2020	43984642	10/07/2020
STRECK		China	43987753	02/03/2020	43987753	10/07/2020
STRECK		China	43985736	02/03/2020	43985736	10/07/2020
STRECK & OWL LOGO	STRECK 	China	43984649	02/03/2020	43984649	08/07/2021
STRECK & OWL LOGO	STRECK 	China	43985736	02/03/2020	43985736	10/07/2020
STRECK (BLOCK LETTERS)	STRECK	China	43987753	02/03/2020	43987753	10/07/2020
STRECK (BLOCK LETTERS)	STRECK	China	43984642	02/03/2020	43984642	10/07/2020

EXHIBIT A – IP Assets

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
STRECK (BLOCK LETTERS)	STRECK	China	61673198	12/24/2021	61673198	09/21/2022

Trademark Applications




Trademark	Mark Image	Country	Application No.	Application Date
STRECK & OWL LOGO	STRECK 	China	36344346	02/15/2019
STRECK & OWL LOGO	STRECK 	China	58629482	08/20/2021
STRECK & OWL LOGO	STRECK 	China	1375949	08/21/2017
STRECK (BLOCK LETTERS)	STRECK	China	58629511	08/20/2021
STRECK (BLOCK LETTERS)	STRECK	China	55358294	04/19/2021
STRECK CELL PRESERVATIVE		China	1568401	11/24/2020

EXHIBIT A – IP Assets

**Colombia**

(i) Copyrights

None

(ii) Patents

None

(iii) Trademarks

Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
STRECK		Colombia	08009387	01/31/2008	367133	11/25/2008

EXHIBIT A – IP Assets

**Czech Republic**

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Preservation of cell-free nucleic acids	CZ 3290530	02/11/2010	09/02/2020

(iii) Trademarks

None

**EXHIBIT A – IP Assets**

**Denmark**

(i) Copyrights

None

(ii) Patents

Patent Registrations

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Method and device for collecting and preserving cells for analysis	DK 1816461	10/16/2003	01/08/2020
Preservation of fetal nucleic acids in maternal plasma	DK 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	DK 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	DK 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	DK 3225699	02/13/2013	09/30/2020

(iii) Trademarks

None

**EXHIBIT A – IP Assets**

**France**

(i) Copyrights

None

(ii) Patents

**Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Inactivated virus compositions and methods of preparing such compositions	FR 2704740	05/03/2012	10/05/2016
Method and device for collecting and preserving cells for analysis	FR 1816461	10/16/2003	01/08/2020
Preservation of fetal nucleic acids in maternal plasma	FR 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	FR 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	FR 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	FR 2814981	02/13/2013	09/30/2020
Assays and methods for determining microbial resistance	FR 3472350	6/15/2017	08/17/2022

(iii) Trademarks

**Trademark Registrations**

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
SICKLEDEX		France	354374	02/25/1969	354374	02/25/1969



**EXHIBIT A – IP Assets**

**Germany**

(i) Copyrights

None

(ii) Patents

Patent Registrations

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Inactivated virus compositions and methods of preparing such compositions	DE 602012023734	05/03/2012	10/05/2016
Method and device for collecting and preserving cells for analysis	DE 60352358.7	10/16/2003	01/08/2020
Method and device for stabilizing proteins	DE 3118623	07/15/2016	05/27/2020
Preservation of fetal nucleic acids in maternal plasma	DE 602010038599	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	DE 2626438	1/21/2010	04/08/2020
Preservation of cell-free nucleic acids	DE 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	DE 602013022817.5	02/13/2013	09/30/2020
Blood Collection Device for Improved Nucleic Acid Regulation	DE 602013073016	02/13/2013	09/30/2020
Thermocycler and sample vessel for rapid amplification of DNA	DE 602009052506	02/19/2009	5/30/2018
Assays and methods for determining microbial resistance	DE 602017060744.4	6/15/2017	08/17/2022

(iii) Trademarks

Trademark Registrations

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
SICKLEDEX		Germany	354374	02/25/1969	354374	02/25/1969

EXHIBIT A – IP Assets

Hong Kong

(i) Copyrights

None

(ii) Patents

Patent Applications

Title	Application Serial No.	Filing Date
Preservation of fetal nucleic acids in maternal plasma	HK 42021027344	03/16/2021
Stabilization of RNA in and extracting from intact cells within a blood sample	HK 17105922	06/04/2017

(iii) Trademarks

Trademark Registrations



Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
OWL LOGO		Hong Kong	305182290	01/30/2020	305182290	01/30/2020
STRECK & OWL LOGO	STRECK 	Hong Kong	305182308	01/30/2020	305182308	01/30/2020
STRECK (BLOCK LETTERS)	STRECK	Hong Kong	305182281A B	01/30/2020	305182281A B	01/30/2020
STRECK (BLOCK LETTERS)	STRECK	Hong Kong	305182281A A	01/30/2020	305182281A A	01/30/2020

EXHIBIT A – IP Assets

Hungary

(i) Copyrights

None

(ii) Patents

None

(iii) Trademarks

Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
SICKLEDEX		Hungary	354374	02/25/1969	354374	02/25/1969

**EXHIBIT A – IP Assets**

**Italy**

(i) Copyrights

None

(ii) Patents

**Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Method and device for collecting and preserving cells for analysis	IT 1816461	10/16/2003	01/08/2020
Preservation of fetal nucleic acids in maternal plasma	IT 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	IT 2626438	01/21/2010	04/08/2020
Assays and methods for determining microbial resistance	IT 3472350	6/15/2017	08/17/2022

(iii) Trademarks

**Trademark Registrations**

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
SICKLEDEX		Italy	354374	02/25/1969	354374	02/25/1969

**EXHIBIT A – IP Assets**

**Japan**

(i) Copyrights

None

(ii) Patents

**Patent Applications**

<b>Title</b>	<b>Application Serial No.</b>	<b>Filing Date</b>
Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles	JP2021500585A	10/19/2018

(iii) Trademarks

**Trademark Registrations**

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
STRECK & OWL LOGO	STRECK®	Japan	A0069781	09/08/2017	1375949	09/08/2017
OWL LOGO	®	Japan	1376232	09/08/2017	1376232	09/08/2017
STRECK (BLOCK LETTERS)	STRECK	Japan	1374838	09/08/2017	1374838	09/08/2017
STRECK CELL PRESERVATIVE		Japan	1568401	11/24/2020	1568401	11/24/2020
THE SCIENCE OF TRUST		Japan	1518684	11/21/2019	1518684	11/21/2019

**Trademark Applications**

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>
ESR-CHEX		Japan	1568347	11/24/2020
MDX-CHEX		Japan	1661752	01/06/2022

EXHIBIT A – IP Assets

**Korea**

(i) Copyrights

None

(ii) Patents

None

(iii) Trademarks

**Trademark Registrations**



Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
ESR-CHEX		Korea	1568347	11/24/2020	1568347	11/24/2020
OWL LOGO		Korea	A0069786	09/08/2017	1376232	09/08/2017
STRECK & OWL LOGO	STRECK 	Korea	A0069781	09/08/2017	1375949	09/08/2017
STRECK (BLOCK LETTERS)	<b>STRECK</b>	Korea	1374838	09/08/2017	1374838	09/08/2017
STRECK CELL PRESERVATIVE		Korea	1568401	11/24/2020	1568401	11/24/2020
THE SCIENCE OF TRUST		Korea	1518684	11/21/2019	1518684	11/21/2019

EXHIBIT A – IP Assets

Luxemburg

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Method and device for stabilizing proteins	LU 3118623	07/15/2016	05/27/2020

(iii) Trademarks

None

EXHIBIT A -- IP Assets

Mexico

(i) Copyrights

None

(ii) Patents

Patent Applications

Title	Application Serial No.	Filing Date
Methods of preparing samples for proteomic analysis	MX/a/2023/000136	01/02/2023

(iii) Trademarks

None



EXHIBIT A – IP Assets

**Montenegro**

(i) Copyrights

None

(ii) Patents

None

(iii) Trademarks

Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
SICKLEDEX		Montenegro	354374	02/25/1969	354374	02/25/1969

EXHIBIT A – IP Assets

**Morocco**

(i) Copyrights

None

(ii) Patents

None

(iii) Trademarks

**Trademark Registrations**

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
SICKLEDEX		Morocco	354374	02/25/1969	354374	02/25/1969

**EXHIBIT A – IP Assets**

**Netherlands**

(i) Copyrights

None

(ii) Patents

Patent Registrations

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Method and device for collecting and preserving cells for analysis	NL 1816461	10/16/2003	01/08/2020
Method and device for stabilizing proteins	NL 3118623	07/15/2016	05/27/2020
Preservation of fetal nucleic acids in maternal plasma	NL 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	NL 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	NL 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	NL 3225699	02/13/2013	09/30/2020

(iii) Trademarks

None

EXHIBIT A – IP Assets

**Panama**

(i) Copyrights



None

(ii) Patents

None

(iii) Trademarks

**Trademark Registrations**

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
OWL LOGO		Panama	281084	06/12/2020	281084	06/12/2020
STRECK & OWL LOGO	STRECK 	Panama	281088	06/12/2020	281088	06/12/2020
STRECK (BLOCK LETTERS)	<b>STRECK</b>	Panama	281084	06/15/2020	281110	06/15/2020

**EXHIBIT A – IP Assets**

**Poland**

(i) Copyrights

None

(ii) Patents

**Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Preservation of fetal nucleic acids in maternal plasma	PL 2228453	01/21/2010	12/07/2016

(iii) Trademarks

None

EXHIBIT A – IP Assets

Portugal

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Preservation of fetal nucleic acids in maternal plasma	PT 2228453	01/21/2010	12/07/2016

(iii) Trademarks

None

**EXHIBIT A – IP Assets**

**Slovak Republic**

(i) Copyrights

None

(ii) Patents

**Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Method and device for collecting and preserving cells for analysis	SK 1816461	10/16/2003	01/08/2020
Preservation of fetal nucleic acids in maternal plasma	SK 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	SK 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	SK 3225699	02/13/2013	09/30/2020

(iii) Trademarks

None

EXHIBIT A -- IP Assets

Serbia

(i) Copyrights

None

(ii) Patents

None

(iii) Trademarks

Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
SICKLEDEX		Serbia	354374	02/25/1969	354374	02/25/1969



**EXHIBIT A – IP Assets**

**Spain**

(i) Copyrights

None

(ii) Patents

**Patent Registrations**

<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Method and device for collecting and preserving cells for analysis	ES 1816461	10/16/2003	01/08/2020
Preservation of fetal nucleic acids in maternal plasma	ES 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	ES 2626438	01/21/2010	04/08/2020
Assays and methods for determining microbial resistance	ES 3472350	6/15/2017	08/17/2022

(iii) Trademarks

**Trademark Registrations**

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
SICKLEDEX		Spain	354374	02/25/1969	354374	02/25/1969

EXHIBIT A – IP Assets

Sweden

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Preservation of fetal nucleic acids in maternal plasma	SE 2228453	01/21/2010	12/07/2016

(iii) Trademarks

None

**EXHIBIT A – IP Assets**

**Switzerland/Lichtenstein**

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Method and device for collecting and preserving cells for analysis	CH 1816461 LI 1816461	10/16/2003	01/08/2020
Preservation of fetal nucleic acids in maternal plasma	CH 2626438 LI 2626438	01/21/2010	04/08/2020
Preservation of fetal nucleic acids in maternal plasma	CH 2228453 LI 2228453	01/21/2010	12/07/2016
Method and device for stabilizing proteins	CH 3118623	07/15/2016	05/27/2020

(iii) Trademarks

Trademark Registrations

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
ESR-CHEX		Switzerland	1568347	11/24/2020	1568347	11/24/2020
SICKLEDEX		Switzerland	354374	02/25/1969	354374	02/25/1969
STRECK CELL PRESERVATIVE		Switzerland	1568401	11/24/2020	1568401	11/24/2020
THE SCIENCE OF TRUST		Switzerland	1518684	11/21/2019	1518684	11/21/2019

EXHIBIT A – IP Assets

Turkey

(i) Copyrights

None

(ii) Patents

Patent Registrations

Title	Patent No.	Date Filed	Issue Date
Preservation of fetal nucleic acids in maternal plasma	TR 2228453	01/21/2010	12/07/2016

(iii) Trademarks

None

**EXHIBIT A – IP Assets**

**United Kingdom**

(i) Copyrights

None

(ii) Patents

Patent Registrations


<b>Title</b>	<b>Patent No.</b>	<b>Date Filed</b>	<b>Issue Date</b>
Inactivated virus compositions and methods of preparing such compositions	GB 2704740	05/03/2012	10/05/2016
Method and device for collecting and preserving cells for analysis	GB 1816461	10/16/2003	01/08/2020
Method and device for stabilizing proteins	GB 3118623	07/15/2016	05/27/2020
Preservation of fetal nucleic acids in maternal plasma	GB 2228453	01/21/2010	12/07/2016
Preservation of fetal nucleic acids in maternal plasma	GB 2626438	01/21/2010	04/08/2020
Preservation of cell-free nucleic acids	GB 3290530	02/11/2010	09/02/2020
Blood Collection Device for Improved Nucleic Acid Regulation	GB 2814981	02/13/2013	09/30/2020
Blood Collection Device for Improved Nucleic Acid Regulation	GB 3225699	02/13/2013	09/30/2020
Sample tube	GB 90021310110001	11/06/2012	11/06/2012
Sample tube	GB 90019285320001	10/06/2011	10/06/2011
Laboratory analysis device housing	GB 90019954240001	02/21/2012	2/21/2012
Laboratory analysis apparatus	GB 90028368820001	10/26/2015	10/26/2015
Assays and methods for determining microbial resistance	GB 3472350	6/15/2017	08/17/2022

(iii) Trademarks

Trademark Registrations

<b>Trademark</b>	<b>Mark Image</b>	<b>Country</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
ARM-D		U.K.	1271279	08/20/2015	1271279	08/20/2015
CD-CHEX		U.K.	UK0091164 7559	03/12/2013	UK00911647 559	09/06/2013
CELL-FREE DNA BCT		U.K.	1161777	05/06/2013	1161777	05/06/2013
CTC PLUS BCT		U.K.	UK0091804 7586	04/03/2019	UK90180475 86	08/30/2019

EXHIBIT A – IP Assets

Trademark	Mark Image	Country	Application No.	Application Date	Registration No.	Registration Date
CTC PLUS BCT		U.K.	UK0000338 9301	04/03/2019	UK00003389 301	06/21/2019
CYTO-CHEX		U.K.	UK0090695 2361	05/30/2008	UK90069523 61	02/10/2009
ESR-CHEX		U.K.	1568347	11/24/2020	1568347	11/24/2020
FUSION2		U.K.	UK0080138 2075	11/14/2017	UK00801382 075	06/05/2018
FUSION2 (Stylized)	<i>FUSION</i>	U.K.	UK0080138 3467	11/14/2017	UK00801383 467	06/06/2018
LBC-CHEX		U.K.	UK0091175 4579	04/19/2013	UK00911754 579	09/12/2013
MDX-CHEX		U.K.	1661752	01/06/2022	1661752	01/06/2022
OWL LOGO		U.K.	87/477123	07/21/2017	UK00801374 847	04/18/2018
PHILISA		U.K.	UK0080105 7134	07/22/2010	UK00801057 134	10/04/2011
PROTEIN PLUS BCT		U.K.	UK0091804 7588	04/03/2019	UK90180475 88	08/30/2019
PROTEIN PLUS BCT		U.K.	UK0000338 9304	04/03/2019	UK00003389 304	06/21/2019
RNA COMPLETE BCT		U.K.	UK0091804 7583	04/03/2019	UK90180475 83	08/30/2019
RNA COMPLETE BCT		U.K.	UK0000338 9297	04/03/2019	UK00003389 297	06/21/2019
STRECK		U.K.	1053091	09/10/2010	1053091	09/10/2010
STRECK (BLOCK LETTERS)	<b>STRECK</b>	U.K.	1375589	08/22/2017	1375589	08/22/2017
STRECK CELL PRESERVATIVE		U.K.	1568401	11/24/2020	1568401	11/24/2020
STRECK STYLIZED - COLOR	<i>Streck</i>	U.K.	UK0090435 4726	03/21/2005	UK00904354 726	04/19/2006
THE SCIENCE OF TRUST		U.K.	1518684	11/21/2019	1518684	11/21/2019
ZULU-RT		U.K.	UK0091552 2031	06/09/2016	UK00915522 031	12/14/2016

PATENT

RECORDED: 07/27/2023

REEL: 064417 FRAME: 0604